New Antibody-Chemo cocktail shows promise for tough lung cancers
NCT ID NCT05215067
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a new drug called AK104 (a bispecific antibody that targets two immune checkpoints) combined with the chemotherapy docetaxel in 44 adults with advanced non-small cell lung cancer whose disease had progressed after platinum-based chemotherapy and an anti-PD-1/PD-L1 drug. The study aimed to see if the combination could shrink tumors and control the disease longer. Results are not yet reported, but the approach tries to boost the immune system while directly killing cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104 (a bispecific antibody targeting PD-1 and CTLA-4) combined with docetaxel chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer whose disease has worsened after standard therapies.
What could go wrong
This is a small, early-phase trial (44 people) with no control group, so results may not be definitive. Side effects from combining immunotherapy and chemotherapy can be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, 210009, China